An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Asthma Drugs Market Oral and injectable forms are expanding, especially for patients with severe asthma and those undergoing biologic treat ...

A single daily preventer dose of inhaled corticosteroid (beclomethasone), taken mid afternoon, may be the best timing for effective asthma control as it suppresses the usual nocturnal worsening of ...

New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

In recent winters, doctors have warned of a potential “ tripledemic ”—a surge of three major respiratory illnesses at once.

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

Inflammatory markers boosted asthma attack prediction, potentially allowing intensification of treatment, according to a meta ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

GSK plc (LSE/NYSE: GSK) today announced the recipients of its COiMMUNITY Initiative grant program, awarding nearly $2 million to 15 regional, state and national non-profits and community-based groups ...

Inflammatory markers play a pivotal role in phenotyping asthma, assessing risks, and tailoring personalised therapeutic strategies, particularly in asthma associated with allergic sensitisation ...